Esomeprazole
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Esomeprazole: From Undocumented Original Indication to Duodenogastric Reflux
One-Sentence Summary
This evidence pack does not record esomeprazole’s original approved indication (data gap), though supporting literature identifies it as a proton pump inhibitor (PPI) used for acid-related disorders. The TxGNN model predicts possible effectiveness for Duodenogastric Reflux (DGR), with a prediction score of 99.53%, but this direction is currently supported by only 1 general review article and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no original indication or marketing-authorisation data recorded) |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for esomeprazole’s original indication is not available in this evidence pack. Based on the supporting literature that is available (PMID 18679668), esomeprazole belongs to the proton pump inhibitor (PPI) class, which acts by suppressing gastric acid secretion and is typically used first-line for peptic ulcer disease, Helicobacter pylori infection, gastro-oesophageal reflux disease, NSAID-induced gastrointestinal lesions, and Zollinger-Ellison syndrome.
Duodenogastric reflux (DGR), however, is primarily driven by reflux of bile and pancreatic secretions into the stomach rather than by excess gastric acid alone. Esomeprazole’s pharmacology only suppresses acid secretion; it has no direct pharmacological action on the bile or alkaline component of reflux. In clinical practice, PPIs are often used empirically in DGR when acid-reflux symptoms coexist, but there is no direct evidence that PPIs address the underlying bile-reflux mechanism of DGR itself.
Taken together, the mechanistic link between esomeprazole and DGR is indirect and only partially substantiated — plausible for symptomatic overlap, but not for the core pathophysiology of the condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Review | European Journal of Clinical Pharmacology | General review of PPI clinical use and pharmacokinetics; establishes PPIs as first-choice therapy for peptic ulcer, H. pylori infection, GORD, NSAID-related GI lesions and Zollinger-Ellison syndrome. Does not specifically address duodenogastric reflux. |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: There are no clinical trials and only a single general PPI review supporting use in duodenogastric reflux, and the proposed mechanism (acid suppression) does not directly address the bile/alkaline reflux component that characterises DGR. Evidence is insufficient to progress beyond model prediction at this stage.
To proceed, the following is needed:
- Original indication and UK marketing-authorisation data for esomeprazole (currently undocumented)
- Detailed mechanism-of-action data (MOA)
- SmPC-level warnings and contraindications (currently a data gap)
- Dedicated clinical studies evaluating esomeprazole specifically in duodenogastric reflux, ideally with bile-reflux-specific endpoints
- DDI data specific to the DGR patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.